Stocks Rise for BioTech Allied With Major Drugmakers (Japan)
This article was originally published in PharmAsia News
Several Japanese biotech companies have gotten a major investment boost of late. The financial windfall comes from a mixture of promising experimental treatments and partnerships with pharmaceutical heavyweights. First off the mark was Japan Tissue Engineering Co. The company got a major break on Oct. 3 when the Japanese Health Ministry gave it the green light to sell cultured skin samples to treat burn wounds. On the same day, Onccotherapy Science Inc. saw heightened investor interest thanks to speculation of a promising new cancer vaccine in development. AnGes MG Inc. and Sosei Group Corp. also saw massive spikes in their earnings between September and October. Experts say their fortunes were helped largely by partnerships with major drug makers. AnGes works with top Japanese firm Daiichi Sankyo, while Sosei partners with Swiss-based international giant Novartis AG. (Click here for more - May Require Paid Subscription
You may also be interested in...
Teligent has achieved a “pivotal step in our journey toward securing a strong financial future,” according to management, after recapitalizing its significant debt burden and gaining access to more cash.
Pfizer has entered into an agreement with Premier to supply five essential medications to US healthcare providers through Premier’s ProvideGx program. Both companies aim to secure supply of products specifically used by COVID patients.
Announcing his “first step to take on pricing of generic drugs,” billionaire Mark Cuban recently associated his name with a new US generics company “to show that capitalism can be compassionate.” In an exclusive chat with Generics Bulletin, the newly established company’s CEO Alex Oshmyansky revealed that they started working on the company “in stealth” since 2018.